TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation

References

• Sami AJ. Structure-function relation of somatotropin with reference to molecular modeling. Curr Protein Pept Sci. 2007 Jun;8(3):283–292.
   PubMed Web of Science ®Google Scholar
• Alatzoglou KS, Turton JP, Kelberman D, et al. Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab. 2009;94(9):3191–3199.
   PubMed Web of Science ®Google Scholar
• Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609.
   PubMed Web of Science ®Google Scholar
• Audí L, Fernández-Cancio M, Camats N, et al. Growth hormone deficiency: an update. Minerva Endocrinol. 2013 Mar;38(1):1–16.
   PubMed Web of Science ®Google Scholar
• Adan L, Trivin C, Sainte-Rose C, et al. GH deficiency caused by cranial irradiation during childhood: factors and markers in young adults. J Clin Endocrinol Metab. 2001 Nov;86(11):5245–5251.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence [internet]. United Kingdom: nice Guidance. Human growth hormone (somatropin) for the treatment of growth failure in children; [cited 2010 May 26]. https://www.nice.org.uk/guidance/ta188/chapter/2-Clinical-need-and-practice.
   Google Scholar
• Lindsay R, Feldkamp M, Harris D, et al. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994 Jul;125(1):29–35.
   PubMed Web of Science ®Google Scholar
• Hartman ML, Crowe BJ, Biller BM, et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab. 2002 Feb;87(2):477–485.
   PubMed Web of Science ®Google Scholar
• Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016;86(6):361–397.
   PubMed Web of Science ®Google Scholar
• Ranke MB. Short and Long-Term Effects of Growth Hormone in Children and Adolescents With GH Deficiency. Front Endocrinol (Lausanne). 2021 Sep 1;12:720419.
   PubMed Web of Science ®Google Scholar
• Yuen KCJ, Miller BS, Boguszewski CL, et al. Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Front Endocrinol (Lausanne). 2021 Feb 24;12:637209.
   PubMed Web of Science ®Google Scholar
• Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79(4):189–196.
   PubMed Web of Science ®Google Scholar
• Loftus J, Chen Y, Alvir JMJ, et al. Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency. Curr Med Res Opin. 2021 Dec;37(12):2141–2150.
   PubMed Web of Science ®Google Scholar
• Kaplowitz P, Manjelievskaia J, Lopez-Gonzalez L, et al. Economic burden of growth hormone deficiency in a US pediatric population. J Manag Care Spec Pharm. 2021 Aug;27(8):1118–1128.
   PubMed Web of Science ®Google Scholar
• Christiansen JS, Backeljauw PF, Bidlingmaier M, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016 Jun;174(6):C1–8.
   PubMed Web of Science ®Google Scholar
• Lippe B, Frasier SD, Kaplan SA. Use of growth hormone-gel. Arch Dis Child. 1979 Aug;54(8):609–613.
   PubMed Web of Science ®Google Scholar
• Silverman BL, Blethen SL, Reiter EO, et al. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab. 2002 May;15(2):715–722.
   PubMed Web of Science ®Google Scholar
• Peter F, Savoy C, Ji HJ, et al. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol. 2009;160(3):349–355.
   PubMed Web of Science ®Google Scholar
• Luo X, Hou L, Liang L, et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. 2017 Aug;177(2):195–205.
   PubMed Web of Science ®Google Scholar
• Hou L, Chen ZH, Liu D, et al. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children. Drug Des Devel Ther. 2015 Dec 18;10:13–21.
   PubMed Web of Science ®Google Scholar
• Johannsson G, Gordon MB, Højby Rasmussen M, et al. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: a Randomized Phase 3 Trial. J Clin Endocrinol Metab. 2020;105(4):e1358–e1376.
   Web of Science ®Google Scholar
• Food and Drug Administration [Internet]. United States: drugs@FDA: FDA-Approved Drugs. Sogroya™ (somapacitan-beco); [ cited 2020 Aug 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf.
   Google Scholar
• Ascendis Pharma [Internet]. United States: ascendis Pharma. TransCon technology [cited 2021 Oct 25]. Available from: https://ascendispharma.com/technology/.
   Google Scholar
• Gilfoyle D, Mortensen E, Christoffersen ED, et al. A first-in-man phase 1 trial for long-acting TransCon Growth Hormone. Growth Horm IGF Res. 2018 Apr;39:34–39.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration [Internet]. United States: drugs@FDA: FDA-Approved Drugs. Skytrofa™ (Lonapegsomatropin-tcgd); [ cited 2021 Aug 25]. cited: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf.
   Google Scholar
• Sprogøe K, inventor; Ascendis Pharma Endocrinology Division A/S, assignee. Long-acting growth hormone dosage forms. United States patent US 2017/0312342 A1. 2017 Dec.
   Google Scholar
• Sprogøe K, inventor; Ascendis Pharma Growth Disorders Division A/S, assignee. Long-acting growth hormone dosage forms. World Intellectual Property Organization patent WO 2016/079302 A1. 2016 May.
   Google Scholar
• Clinical Trials [Internet]. United States: Clinical Trials. TransCon Hgh; [cited 2021 Oct 25]. Available from: https://clinicaltrials.gov/ct2/home.
   Google Scholar
• Food and Drug Administration [Internet]. United States: drugs@FDA: FDA-Approved Drugs. Genotropin® (somatropin); [ cited 2021 Dec 24]. cited: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020280s088lbl.pdf.
   Google Scholar
• GoodRX.com [Internet]. United States of America: goodRx; 2021 [cited 2021 Dec 24]. Available from: https://www.goodrx.com/
   Google Scholar
• Drugs.com [Internet]. New Zealand: DrugSite Trust; 2021 [cited 2021 Dec 24]. Available from: https://www.drugs.com/
   Google Scholar
• Chatelain P, Malievskiy O, Radziuk K, et al. A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. J Clin Endocrinol Metab. 2017 May 1;102(5):1673–1682.
   PubMed Web of Science ®Google Scholar
• Thornton PS, Maniatis AK, Aghajanova E, et al. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: the Phase 3 heiGHt Trial. J Clin Endocrinol Metab. 2021 Oct 21;106(11):3184–3195.
   PubMed Web of Science ®Google Scholar
• Sprogøe K, Mortensen E, Karpf DB, et al. The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency. Endocr Connect. 2017;6(8):R171–R181.
   PubMed Web of Science ®Google Scholar
• Höybye C, Pfeiffer AF, Ferone D, et al. A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. Endocr Connect. 2017 Apr;6(3):129–138.
   PubMed Web of Science ®Google Scholar